glp-1 ban FDA is moving to restrict mass-marketed compounded products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified How GLP-1 medications are transforming

doi: 10.1016/j.soard.2019.06.022 16 JerlhagE.EgeciogluE.DicksonS

Overall, about one in five (22%) adults who are not currently taking GLP-1 drugs (88% of the public) say they would be interested in taking a GLP-1 drug to lose weight, including just 7% who say they would be very interested. This rises to four in ten (43%) among adults who are not currently taking a GLP-1 but report being diagnosed as overweight or obese in the past five years, and about one in four (27%) among those who say they have been diagnosed with diabetes or heart disease

El mecanismo de accin de estos frmacos es debido a mltiples efectos, como su efecto incretina con aumento de la secrecin de insulina por las clulas beta, mejora en la sensibilidad de la insulina, disminucin de la secrecin de glucagn y reduccin en la ingesta de alimentos por induccin de saciedad11,45

Diagnosis and classification of Graves disease